First Trust Advisors LP bought a new stake in shares of Dermira, Inc. (NASDAQ:DERM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,281 shares of the biopharmaceutical company’s stock, valued at approximately $1,174,000. First Trust Advisors LP owned approximately 0.10% of Dermira as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Legal & General Group Plc raised its position in Dermira by 16.3% during the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 963 shares in the last quarter. Granite Point Capital Management L.P. raised its position in Dermira by 3.1% during the 1st quarter. Granite Point Capital Management L.P. now owns 38,150 shares of the biopharmaceutical company’s stock valued at $1,301,000 after purchasing an additional 1,150 shares in the last quarter. Alliancebernstein L.P. raised its position in Dermira by 4.5% during the 1st quarter. Alliancebernstein L.P. now owns 41,600 shares of the biopharmaceutical company’s stock valued at $1,419,000 after purchasing an additional 1,800 shares in the last quarter. Nationwide Fund Advisors raised its position in Dermira by 6.5% during the 1st quarter. Nationwide Fund Advisors now owns 30,609 shares of the biopharmaceutical company’s stock valued at $1,044,000 after purchasing an additional 1,867 shares in the last quarter. Finally, American International Group Inc. raised its position in Dermira by 23.4% during the 1st quarter. American International Group Inc. now owns 14,900 shares of the biopharmaceutical company’s stock valued at $508,000 after purchasing an additional 2,829 shares in the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on DERM shares. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Mizuho reaffirmed a “buy” rating and set a $43.00 target price (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. BidaskClub lowered Dermira from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 target price on shares of Dermira in a research report on Tuesday, July 18th. Finally, Cantor Fitzgerald started coverage on Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 target price for the company. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $44.40.

In related news, insider Eugene A. Bauer sold 2,500 shares of Dermira stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $30.00, for a total value of $75,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Fred B. Craves bought 30,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $23.03 per share, with a total value of $690,900.00. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 9,200 shares of company stock valued at $262,512. 13.30% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “First Trust Advisors LP Takes $1.17 Million Position in Dermira, Inc. (DERM)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/19/first-trust-advisors-lp-takes-1-17-million-position-in-dermira-inc-derm.html.

Shares of Dermira, Inc. (NASDAQ DERM) opened at 27.52 on Tuesday. The firm’s 50-day moving average price is $24.55 and its 200-day moving average price is $29.49. Dermira, Inc. has a 12 month low of $21.35 and a 12 month high of $38.75. The company’s market capitalization is $1.14 billion.

Dermira (NASDAQ:DERM) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.00 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. Equities research analysts expect that Dermira, Inc. will post ($4.20) EPS for the current year.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira, Inc. (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.